 | | Vol. 14.02 – 20 January, 2022 |
| |
|
|
| Researchers leveraged global transcriptome and accompanying epigenome-wide changes in 48 umbilical cord blood (UCB) from newborns of early pregnancy (EP)-anemic Tanzanian mothers and 50 controls to identify differentially expressed genes in UCB exposed to maternal EP-anemia.
[Journal of Clinical Endocrinology & Metabolism] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists ascertained the expression of tissue factor in a HTR-8/SVneo trophoblast cell line and its role in signal transduction of integrin regulation concerning the invasion of trophoblasts.
[Journal of Reproductive Immunology] |
|
|
|
| Gold labelled lectin histochemistry and protein immunocytochemistry were used on deplasticised 1 μm sections of a wide variety of ruminant placentomes with a wide range of antibodies and lectins.
[Biology of Reproduction] |
|
|
|
| Scientists reported the presence of nuclear factor erythroid 2-related factor (Nrf)1, Nrf2 and Nrf3 proteins in both human primary trophoblast and human trophoblast choriocarcinoma cell line.
[Placenta] |
|
|
|
| MTA1 upregulates trophoblasts proliferation and differentiation, while MTA3 downregulates proliferation and induces apoptosis. Researchers hypothesized that during intrauterine growth restriction, placental MTA1 decreased and MTA3 increased and this was reversed by P4 treatment.
[Molecular Biology Reports] |
|
|
|
| Investigators encountered a case of human platelet antigen 15 (HPA-15) mismatched cord blood transplantation with a high HPA-15b antibody titer. Prolonged poor graft function and megakaryocyte aplasia with sustained high-titer HPA-15b antibodies were attenuated by rituximab therapy.
[International Journal of Hematology] |
|
|
|
|
| Scientists highlight the development of the amniotic-membrane over the years and the implication of new and emerging nanotechnology to support expanding its use for tissue engineering and clinical applications.
[Stem Cell Research & Therapy] |
|
|
|
| The authors discuss the current human and rodent studies that have examined the effects of opioids on the placenta.
[Biology of Reproduction] |
|
|
|
|
| IMV, Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.
[IMV, Inc.] |
|
|
|
|
|
|
|
| Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| Fox Chase Cancer Center, Temple University – Philadelphia, Pennsylvania, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
